Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
September 27 2024 - 2:00PM
Neurona Therapeutics, a clinical-stage biotherapeutics company
advancing regenerative cell therapies for disorders of the nervous
system, today announced that Cory R. Nicholas, Ph.D., Neurona’s
Co-Founder and Chief Executive Officer, will participate in the
following investor conferences in October:
2024 William Blair’s Innovator Series:
Private Biotechnology StarsFormat:
Fireside ChatDate/Time: Thursday, October 3, at
6:00 am PT / 8:00 am CTLocation: Virtual
Leerink Partners Biopharma Private
Company ConnectFormat: 1x1 Investor
MeetingsDate/Time: Tuesday, October 22 and
Wednesday, October 23Location: Virtual
A replay of the fireside chat at the 2024
William Blair’s Innovator Series: Private Biotechnology Stars will
be available in the News section of the Neurona website under
Events for 7 days following the event.
About Neurona Therapeutics
Neurona is developing allogeneic, off-the-shelf,
regenerative neural cell therapy products with the potential to
provide long-term targeted repair of the nervous system following a
single administration. The Company’s lead product candidate
NRTX-1001, comprising GABAergic interneurons, is currently being
studied for safety and efficacy in two ongoing open label
multicenter Phase 1/2 trials (NCT05135091) for drug-resistant
unilateral mesial temporal lobe epilepsy and (NCT06422923) for
drug-resistant bilateral mesial temporal lobe epilepsy, with
neocortical focal epilepsy and other indications planned in the
future. The Phase 1 of the unilateral MTLE clinical trial is
supported by an $8.0 million grant from the California Institute
for Regenerative Medicine (CIRM; CLIN2-13355). The FDA granted the
Regenerative Medicine Advanced Therapy (RMAT) designation to
NRTX-1001 in June 2024 based on positive clinical data from the
ongoing Phase 1/2 trial in unilateral MTLE, for which the most
recent data update was presented at the American Academy of
Neurology Annual Meeting in April 2024. In February 2024, Neurona
raised $120 million in a private financing co-led by Viking Global
Investors and Cormorant Asset Management. For more information
about Neurona, visit: www.neuronatherapeutics.com.
Investor Contact:Laurence WattsNew Street
Investor Relationslaurence@newstreetir.com